

Review

Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer

Farhoud Faraji^{1,2,3,*} , Sydney I. Ramirez^{3,4}, Paola Y. Anguiano Quiroz⁵, Amaya N. Mendez-Molina⁶ and J. Silvio Gutkind^{2,3,*}

¹ Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA 92093, USA

² Gleiberman Head and Neck Cancer Center, University of California San Diego Health, La Jolla, CA 92093, USA

³ Department of Pharmacology, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA; sir011@health.ucsd.edu

⁴ Division of Infectious Disease and Global Public Health, Department of Internal Medicine, University of California San Diego, La Jolla, CA 92037, USA

⁵ John Muir College, University of California San Diego, La Jolla, CA 92093, USA; panguianoquiroz@ucsd.edu

⁶ Eleanor Roosevelt College, University of California San Diego, La Jolla, CA 92093, USA; amendezmolina@ucsd.edu

* Correspondence: f1faraji@health.ucsd.edu (F.F.); sgutkind@health.ucsd.edu (J.S.G.)

Abstract: Head and neck squamous cell carcinoma (HNSCC) represents a highly prevalent and deadly malignancy worldwide. The prognosis for locoregionally advanced HNSCC has not appreciably improved over the past 30 years despite advances in surgical, radiation, and targeted therapies and less than 20% of HNSCC patients respond to recently approved immune checkpoint inhibitors. The Hippo signaling pathway, originally discovered as a mechanism regulating tissue growth and organ size, transduces intracellular and extracellular signals to regulate the transcriptional co-activators YAP and TAZ. Alterations in the Hippo pathway resulting in persistent YAP and TAZ activation have emerged as major oncogenic drivers. Our analysis of the human HNSCC oncogenome revealed multiple genomic alterations impairing Hippo signaling and activating YAP and TAZ, which in turn contribute to HNSCC development. This includes mutations and deletions of the FAT1 gene (29%) and amplification of the WWTR1 (encoding TAZ, 14%) and YAP1 genes (8%), together representing one of the most genetically altered signaling mechanisms in this malignancy. Here, we discuss key elements of the mammalian Hippo pathway, detail mechanisms by which perturbations in Hippo signaling promote HNSCC initiation and progression and outline emerging strategies to target Hippo signaling vulnerabilities as part of novel multimodal precision therapies for HNSCC.

Keywords: head and neck squamous cell carcinoma; HNSC; HNSCC; Hippo; YAP; TAZ; FAT1



Citation: Faraji, F.; Ramirez, S.I.; Anguiano Quiroz, P.Y.; Mendez-Molina, A.N.; Gutkind, J.S. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer. *Cells* **2022**, *11*, 1370. <https://doi.org/10.3390/cells11081370>

Academic Editors: Wanjin Hong and Lanfen Chen

Received: 28 March 2022

Accepted: 15 April 2022

Published: 18 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) encompasses a heterogeneous group of malignancies arising from the upper aerodigestive tract epithelia lining the oral cavity, oropharynx, hypopharynx, and larynx. With nearly 745,000 new cases and greater than 360,000 deaths annually worldwide in 2020, HNSCC remains a major global cause of morbidity and mortality [1–3]. Two carcinogenic etiologies underlie most HNSCC: viral infection, primarily with human papillomavirus (HPV), and chemical carcinogen exposure via the use of tobacco products, alcohol, and betel quid [4]. Although some subtypes of nasopharyngeal carcinoma (NPC), an Epstein-Barr virus-associated cancer endemic to southern China, Southeast Asia, and North Africa, share features with virally-mediated HNSCC, it is considered a pathologically distinct malignancy, and therefore, will not be further reviewed here [5,6].

The great majority of HNSCC patients present with locoregionally advanced disease with cervical lymph node metastases and face 5-year overall survival rates ranging from 50–66% [7,8]. The prognosis for locoregionally advanced HNSCC has not appreciably improved over the past 30 years despite notable advances in surgical, radiation, and systemic oncotherapies [9]. Furthermore, while immune checkpoint inhibition (ICI) immunotherapies represent a novel treatment option for recurrent and metastatic HNSCC, the objective response rate to ICI is only approximately 20% [10,11]. These unfortunate realities underscore the need for a more detailed understanding of the biological processes underlying HNSCC carcinogenesis, progression, recurrence, and therapeutic resistance.

The Hippo pathway is a signaling cascade that integrates intracellular and extracellular signals to control cell proliferation, self-renewal, differentiation, apoptosis, and organ size [12,13]. Over the past two decades, the Hippo pathway has emerged as a tumor suppressive mechanism [14]. Comprehensive molecular characterization of cancer-associated mutations has identified alterations in the Hippo cascade and its effectors YAP and TAZ as dominant oncogenic drivers in a variety of malignancies, including HNSCC [15]. Intensive investigation of Hippo and YAP/TAZ in cancer has elucidated novel oncogenic mechanisms and has shed light on new therapeutically actionable cancer vulnerabilities [16–18]. In this review, we describe key elements of the Hippo pathway in mammals, detail mechanisms by which perturbations in Hippo signaling promote HNSCC initiation and progression and outline emerging strategies to target Hippo signaling vulnerabilities as part of novel precision therapies for HNSCC.

2. Elements of the Hippo-YAP/TAZ Pathway

The Hippo signaling pathway was initially discovered as a mechanism that restricted tissue overgrowth in *Drosophila* [13,19]. Since its discovery, Hippo signaling was revealed to be highly conserved and to play pleiotropic roles in tissue homeostasis across a diversity of organisms. These insights have led to widespread interest in understanding Hippo pathway roles and regulatory mechanisms in physiology and disease [12]. The association of Hippo pathway alterations with a variety of cancers has led to the highest interest in understanding mechanisms by which the Hippo pathway initiates tumorigenesis, aimed at the development of new targeted approaches for cancer prevention and treatment.

Multiplatform pan-cancer analyses have identified recurrent Hippo pathway alterations across the majority of cancer types evaluated [15]. Such pan-cancer analyses have shown that Hippo signaling alterations leading to YAP/TAZ activation are particularly abundant in squamous cell carcinoma (SCC). Cervical, lung, head and neck, bladder, and esophageal SCC rank among malignancies with the highest YAP/TAZ amplification frequencies, suggesting that YAP/TAZ activation represents a particularly important role in squamous cancers [15].

The Core Hippo Kinase Cascade

The canonical model of Hippo signaling is centered on two “core” kinases and their respective regulatory proteins. The paralogs MST1 (SKT4) and MST2 (STK3) (henceforth collectively referred to as MST1/2) represent the upstream kinases of the core Hippo pathway. Diverse cellular signals activate the Hippo pathway via phosphorylation of MST1/2. In turn, MST1/2 regulates the activity of the downstream paralogous kinases LATS1 and LATS2 (LATS1/2). Phosphorylation of MST1/2 promotes its heterodimerization with SAV1, potentiating MST1/2 kinase activity to recruit and phosphorylate LATS1/2 and the LATS1/2 scaffold protein MOB1A/B [20,21]. Of note, LATS1/2 phosphorylation can also occur independently of MST1/2. MAP4K1/2/3/5, MAP4K4/6/7, and TAOK1/2/3 have been shown to directly activate LATS1/2 in an MST1/2-independent manner, thus demonstrating a partially redundant and overlapping role for MAP4Ks with MST1/2 in the core Hippo pathway [22,23]. Once LATS1/2 and MOB1A/B are phosphorylated, the activated phospho-LATS1/2:phospho-MOB1A/B complex then phosphorylates YAP (YAP1) and TAZ (WWTR1) (Figure 1) [24].




Figure 1. The Core Hippo Pathway. In the absence of Hippo-stimulating signals (**left**), the core Hippo kinase cascade is inactive and YAP/TAZ translocate into the nucleus to associate with TEAD family DNA binding proteins and co-activate transcriptional programs. In the presence of Hippo-stimulating signals (**right**), MST1/2 is phosphorylated and subsequently phosphorylates SAV1, LATS1/2, and MOB1A/B. In turn, LATS1/2 phosphorylates YAP/TAZ, resulting in YAP/TAZ cytoplasmic retention or proteolytic decay. Of note, Hippo-stimulating signals may bypass MST1/2 and directly activate LATS1/2.

YAP and TAZ are paralogous proto-oncogenic transcriptional coactivators controlling the expression of cell proliferation, survival, self-renewal, and migration programs. Induction of YAP/TAZ-mediated transcriptional programs requires nuclear entry and interaction with DNA-binding proteins. Under physiologic conditions, the Hippo pathway regulates the cellular localization and stability of YAP and TAZ [25]. In fact, YAP/TAZ activation is regulated by a Hippo-dependent negative feedback loop, in which YAP/TAZ activation drives the expression of Hippo pathway components, such as AMOTL2, NF2, and LATS2, which in turn promote compensatory YAP/TAZ inhibition [12,26,27]. Specifically, YAP/TAZ phosphorylation promotes binding to 14-3-3 family proteins, resulting in YAP/TAZ cytoplasmic retention and functional inactivation. Furthermore, LATS1/2-induced phosphorylation can also promote further phosphorylation of cytoplasmic YAP/TAZ by casein kinase 1 (CK1), ultimately leading to YAP/TAZ ubiquitination and proteolytic degradation [24,28,29]. LATS1/2-mediated YAP/TAZ nuclear exclusion and proteolytic degradation, resulting in YAP/TAZ inhibition, represent the dominant output of Hippo pathway activation.

3. Upstream Hippo Regulators

Physiological organ development and growth require cells to sense and adapt to multicellular-scale environmental cues. The Hippo pathway has emerged as a signaling hub through which cells respond to the tissue environment by activating transcriptional programs (Figure 2). The Hippo pathway has been shown to cooperate with multiple tumor suppressors to sense and respond to upstream signals. These signals include cell-cell contact, cytoskeleton and cell shape, the extracellular matrix, and integral membrane receptor signaling [30–32]. Indeed, genetic disturbances in Hippo components in model organisms result in organ and tissue overgrowth phenotypes, suggesting the Hippo pathway is necessary to regulate cellular proliferation to maintain normal tissue architecture and organ size [33]. Acquired and inherited Hippo pathway alterations disrupt these homeostatic processes and can trigger neoplastic transformation [34–36].




Figure 2. Hippo Pathway Regulation. A variety of mechanisms stimulate or inhibit core Hippo kinases including adherens and tight junctions, focal adhesions complexes, growth factor receptor tyrosine kinase (RTK) and G protein coupled receptors (GPCRs), and the actin cytoskeleton, as well as proto-cadherins of the FAT family. Solid arrows indicate evidence of direct interaction. Broken arrows indicate evidence of indirect or multistep interactions not detailed in this figure. Please see the text for further detail.

Direct Regulators of Core Hippo Kinases

MST1/2 phosphorylation is regulated by a variety of upstream inputs, including the PP2A complex striatin-interacting phosphatase and kinase (STRIPAK) and the tumor suppressor RASSF1A. In the setting of MST1/2 phosphorylation, STRIPAK is recruited to and binds MST1/2 via its Sarcolemma Associated Protein (SLMAP) subunit, resulting in MST1/2 dephosphorylation and inactivation [12,13]. STRIPAK dephosphorylation of MST1/2 is antagonized by the SAV1 regulatory subunit of MST1/2 as well as by RASSF1A [37,38]. STRIPAK is also involved in the regulation and inhibition of the MAP4K4/6/7 family proteins, further demonstrating a key role for STRIPAK in the regulation of the Hippo pathway [20,39]. FRMD6 is a tumor suppressor that regulates Hippo signaling by phosphorylating core Hippo kinases MST1/2 and LATS1. In addition, the N-terminal FERM domain of FRMD6 antagonizes YAP in the setting of FRMD6 overexpression [40]. NF2 represents an upstream activator of Hippo signaling both by interacting with AMOT to enhance LATS kinase activity and as a direct inhibitor of YAP/TAZ activity (Figure 2) [27,41,42].

4. Non-Hippo Signaling Inputs

4.1. Receptor Tyrosine Kinases, RAS, and Mitogen Activated Protein Kinases

Multiple mitogenic signal transduction pathways converge on Hippo core kinase inhibition with subsequent YAP activation. In one proposed mechanism, EGFR-RAS-MAPK signaling activation results in p-ERK-mediated phosphorylation of the AJUBA family protein WTIP. Phosphorylated WTIP demonstrates increased binding to the Hippo pathway members LATS1 and SAV1, thereby diminishing core Hippo kinase activity [43]. The receptor tyrosine kinase EGFR also has been shown to activate YAP/TAZ independently of PI3K

through the direct phosphorylation of MOB1A; this is discussed in detail below (please see 'FAT1-Independent Mechanisms of Oncogenic Hippo Pathway Perturbation in HNSCC') [44].

4.2. G-Protein Coupled Receptors

G-protein coupled receptor (GPCR) signaling also constitutes a signaling input into the Hippo pathway and regulates Hippo activity in a class-dependent manner. $G_{12/13}$ - and $G_{q/11}$ -coupled receptors inhibit LATS1/2, while G_s -coupled receptors activate LATS1/2 [45]. G_s -PKA signaling regulates the Hippo pathway through PKA-mediated phosphorylation of LATS1/2, which promotes YAP phosphorylation and inhibition [45]. Phosphorylation and inactivation of YAP is required for cell cycle exit and terminal differentiation, and PKA plays a role in regulating YAP activity [46,47]. Meanwhile, YAP/TAZ have been demonstrated to be required for signal transduction of the $G_{12/13}$ - and $G_{q/11}$ -coupled receptor agonist LPA and LPA-promoted cellular migration and proliferation [44]. In the context of malignancy, oncogenic $G_{q/11}$ mutant signaling requires YAP activation to drive tumor initiation and progression [48,49]. Importantly, genetic analysis of the signaling pathway by which mutant $G_{q/11}$ activates YAP has helped identify synthetic lethal interactions between gain-of-function $G_{q/11}$ mutations and the non-receptor tyrosine kinase FAK. This interaction has unveiled a critical vulnerability in $G_{q/11}$ mutant cells to FAK inhibition via the disruption of YAP-activation [50].

Genetic ablation of *Gnas* or inhibition of PKA in the epidermis can result in the dramatic expansion of the stem cell compartment, whereas G_s -PKA overactivation through the GNAS R201C mutation can drive terminal differentiation and exhaustion of the same stem cell population [51,52]. Mechanistically, this stem cell expansion is mediated in part by the loss of G_s -PKA-mediated inhibition of YAP; without having a demonstrable effect on Wnt/ β -catenin-mediated stem cell programs [51], thus demonstrating that G_s -PKA can regulate YAP/TAZ independently of the Wnt/ β -catenin signaling pathway.

4.3. Wnt/ β -Catenin

In the absence of Wnt signaling, cytoplasmic YAP/TAZ directly binds to Axin and acts as an integral part of the β -catenin destruction complex [52]. As the main scaffold protein for the assembly of the destruction complex, Axin plays a key role in regulating Wnt/ β -catenin signaling as well as YAP/TAZ subcellular localization. Axin directly binds GSK3 and YAP/TAZ, which in turn phosphorylate β -catenin and recruit the β -TrCP ubiquitin ligase, respectively. Ultimately, the formation of the phospho- β -catenin/TAZ/ β -TrCP complex results in both TAZ and β -catenin proteasomal degradation. Conversely, in the presence of WNT, LRP6 competitively inhibits the binding of YAP/TAZ to Axin, releasing YAP/TAZ from the destruction complex to translocate to the nucleus, and freeing β -catenin (and TAZ) from destruction complex-mediated degradation [53].

β -catenin activity is also regulated by G_s -PKA signaling [52]. G_s -PKA interactions with Axin and other members of the destruction complex lead to the stabilization and activation of β -catenin [54]. This occurs through multiple mechanisms: (1) direct interaction of G_s with Axin to promote β -catenin activity, (2) PKA-mediated phosphorylation of GSK3 to release β -catenin from the destruction complex and allow it to translocate to the nucleus, and (3) PKA phosphorylation of β -catenin to inhibit β -catenin ubiquitination and subsequent proteasomal degradation [52,55,56]. Thus, G_s -PKA signaling can also promote Wnt/ β -catenin activity independently of its role in Hippo-YAP/TAZ regulation.

5. Mechanical Hippo Inputs

5.1. Cell Contact, Cell Shape, and the Actin Cytoskeleton

Changes in cell shape and cytoskeletal organization induced by cell density signaling can be transduced through the Hippo pathway thereby controlling YAP/TAZ subcellular localization. Contact inhibition describes an arrest in cell proliferation that occurs when cells reach high cell density. High cell density induces LATS1/2 kinase activity with subsequent YAP/TAZ phosphorylation, resulting in YAP/TAZ interaction with 14-3-3 and

YAP/TAZ cytoplasmic sequestration [24,57]. The YAP/TAZ:14-3-3 complex limits YAP dephosphorylation by PP2A phosphatases. Removal of cell-cell contacts relieves PP2A inhibition, allowing for YAP-dephosphorylation, nuclear translocation, and activation of transcriptional programs that drive cell cycle re-entry. YAP activation in cancer is observed in cells that have lost cell contact sensing mechanisms, indicating that relief from contact inhibitory sensing abolishes Hippo signaling and unleashes YAP oncogenic function [24].

In parallel, at high cellular density, individual cells display reductions in the substrate-adherent cell surface area and decreased cytoskeletal tension. Such conditions result in the inhibition of Rho-GTPase activity, reduction of F-actin stress fiber formation, and YAP/TAZ inactivation. Rho- and F-actin polymerization-mediated regulation of YAP/TAZ subcellular localization may occur through Hippo-dependent mechanisms, including Rho:LIMD1-mediated inactivation of LATS1/2 (see below) [58]. In the absence of YAP-mediated cell cycle progression, the quiescent cell state can be reversed through induction of mechanical stretch, which induces E-cadherin to release YAP from the plasma membrane, enabling YAP nuclear translocation to activate cell cycle re-entry [59].

YAP/TAZ activity can be regulated by multiple Hippo pathway-independent mechanisms. Several proteins, including α -catenin, AMOT, PTPN14 and CDK1 can inhibit YAP/TAZ by directly binding and sequestering them in the cytoplasm [24,33,60]. Adherens junctions and tight junctions constitute two distinct cell-cell adhesion complexes implicated in Hippo activation. At adherens junctions, E-cadherin dimerization recruits α - and β -catenin to induce MST1/2 phosphorylation in conjunction with tumor suppressors Kibra (WWC1) and NF2 [61]. In epidermal epithelia, such as those of the upper aerodigestive tract, adherens junctions function in sensing epidermal cell density and restricting basal cell proliferation. In this regard, α -catenin is involved in sensing cell density and exerting a negative regulatory effect on YAP in cell-dense conditions. Given its role in YAP inactivation in the setting of contact inhibition, preventing inappropriate cellular proliferation, α -catenin can be considered a tumor suppressor [57]. At tight junctions, the angiominin (AMOT) complex mediates contact inhibition by (1) directly binding and sequestering YAP at the plasma membrane and (2) activating LATS1/2 kinase activity through the tumor suppressor Merlin (NF2) [62].

5.2. The Extracellular Matrix

The extracellular matrix (ECM) acts both as a scaffold for cell adhesion and spread as well as a source of physical cues that influence cellular growth and survival. ECM stiffness is one of the principal determinants of cellular attachment and spreading. As such, it also plays roles in cellular growth, migration, and differentiation; in part through alterations in Hippo pathway signaling and YAP/TAZ subcellular localization.

Cellular attachment to the ECM increases nuclear YAP through activation of signaling pathways including FAK-Src, Integrin-PI3K, and Rho-GTPases [63–65]. Increased mechanical strain leads to JNK-mediated phosphorylation of the AJUBA family protein LIMD1. Phosphorylated LIMD1 can bind to and inactivate LATS1/2, decreasing LATS1/2-mediated phosphorylation of YAP and promoting YAP nuclear translocation [58].

Regulation of YAP/TAZ subcellular localization by ECM rigidity is also mediated by changes in cell shape and cytoskeletal tension. As noted above, F-actin polymerization and Rho-GTPases play an integral role in the regulation of YAP/TAZ translocation by mechanotransduction. RhoA GTPase activity promotes actin polymerization and stress fiber formation, thereby altering cell shape and adhesive surface area. Disruption of F-actin decreases nuclear YAP. Hippo-mediated transduction of mechanical forces into transcriptional programs of cell growth and differentiation is proposed to function as a checkpoint during stem cell development and may have implications for cancer stem cells [66].

Tumor tissue is often characterized by stiffness attributable to higher collagen expression and increased collagen cross-linking [67]. Increased lysyl oxidase (LOX) enzyme activity in tumor tissue creates increased numbers of cross-links between collagen and

other ECM components [68,69]. Tumor cell proliferation, differentiation, migration, and invasion are influenced by the rigidity of the tumor tissue. Given the role of Hippo signaling in sensing ECM stiffness, such conditions are likely to induce YAP activation, which in turn mediates tumor cell proliferation, differentiation, migration, and invasion programs attributed to ECM-stiff tumors [68,70].

6. Functions of Hippo Pathway Effectors: YAP and TAZ

6.1. Proliferation

Of direct relevance to squamous carcinogenesis, YAP has been demonstrated to promote the proliferation of progenitor cells in the epidermis [57,71]. Transgenic mouse models carrying an active YAP allele (YAP^{S127A}) that is not subject to regulation by cytoplasm-restricting phosphorylation have demonstrated that uncontrolled YAP activation drives the expansion of proliferating basal epidermal cells of the skin and oral cavity. Conversely, knockout of YAP resulted in failure of normal skin development and loss of epidermal barrier function. TEAD family DNA binding proteins represent the major transcriptional partners for YAP in the context of epidermal development, and TEAD cellular distribution mirrors that of YAP activation, with cells exhibiting the highest proliferative activity and nuclear YAP localization also exhibiting strong TEAD expression [57].

Chromatin immunoprecipitation analyses have informed the landscape of genome-wide YAP/TAZ and TEAD binding, revealing that TEAD4 binding sites overlap with 78% of YAP/TAZ sites. Surprisingly, the overwhelming majority (89%) of YAP/TAZ/TEAD binding was found to occur at active enhancer elements marked by histone H3 monomethylation at lysine 4 residue (H3K4me1) and acetylation of lysine 27 (H3K27ac), while very few YAP/TAZ/TEAD peaks (3.6%) occurred at promoters. Greater than a third of the YAP/TAZ/TEAD direct target genes constituted a cell-proliferation program of essential factors involved in replication licensing, DNA synthesis and repair, transcriptional regulators of the cell cycle, cyclins and their activators, and factors required for completion of mitosis [72]. Taken together, these findings suggest that the YAP/TAZ/TEAD complex functions at distal enhancers to activate a transcriptional program to induce cell cycle progression. Indeed, depletion of YAP/TAZ or TEAD resulted in a severe reduction of cells in the S and G2/M phases of the cell cycle and an expansion of cells arrested in G1, demonstrating the necessity of YAP/TAZ in proliferation through interactions with TEAD family proteins [72].

6.2. Stemness

YAP/TAZ have been implicated as regulators of stem cell maintenance in multiple systems. YAP is elevated during induced pluripotent stem cell reprogramming and embryonic stem cells (ES) lose their pluripotent potential with YAP depletion. Embryonic stem cell differentiation is prevented by ectopic YAP expression. Genome-wide analysis helped to elucidate the role of YAP in ES differentiation, demonstrating that many YAP-inducible genes contain TEAD-binding sites that are bound by YAP and that YAP regulation of ES stemness occurs through YAP-mediated transcriptional activation of programs of ES pluripotency and self-renewal, including Sox2, Nanog, and Oct4 [73].

In the epidermis, enforced YAP activation disrupts normal epidermal stratification by both promoting expansion of the progenitor cell compartment into the suprabasal epidermal layers and preventing differentiation of these cells [57]. By depleting YAP/TAZ in cells grown at different densities and on substrates that provided different mechanosensory inputs, it was demonstrated that YAP/TAZ depleted cells exit the cell cycle and concomitantly lose expression of basal/stem cell markers while gaining expression of terminal differentiation markers; YAP/TAZ is excluded from the nuclei of differentiated cells. Conversely, ectopic expression of YAP^{5SA}, which lacks inhibitory phosphorylation sites, prevents epidermal cell differentiation regardless of cell density or substrate composition [25].

In contrast to YAP/TAZ activity, Notch signaling is enhanced by low mechanical strain as experienced by cells grown on soft substrates, at higher cell density, or in the context of

F-actin inhibition [25]. Inhibition of Notch signaling through various methods consistently prevented YAP/TAZ depleted cells from undergoing differentiation [25]. The opposing actions of YAP/TAZ and Notch in epidermal progenitor cell differentiation were recapitulated in vivo. YAP/TAZ are transcriptional co-activators that typically control transcription through binding enhancers distant to the transcription start site. Mechanistically, YAP/TAZ antagonizes Notch signaling ‘in cis’ through transcriptional activation of Notch inhibitors, including Delta-like ligands (DLL), promoting maintenance of epidermal stemness and inhibiting differentiation [25].

7. The Landscape of Hippo Pathway Alteration in HNSCC

Genome-wide molecular profiling efforts have provided detailed mutational landscapes of cancer and identified *TP53* (72%), *CDKN2A* (54%), *PIK3CA* (35%), *FAT1* (29%), and *NOTCH1* (21%) as the most frequently altered genes in HNSCC [74]. Moreover, these and our efforts have revealed Hippo pathway alterations as recurrent events in HNSCC [15,75]. The top ten most frequently altered Hippo pathway genes are mutated or altered in 61% (309/504) of patients with HNSCC and, among Hippo pathway altered HNSCCs, nearly half (47%, 144/309) possess two or more alterations in these commonly mutated Hippo genes. Consistent with their roles in oncogenesis, tumor suppressive Hippo genes predominantly undergo inactivating mutation and deletion, while oncogenic Hippo genes show amplification (Figure 3) [75–77]. These observations support the emerging importance of Hippo function in the upper aerodigestive tract epithelia and indicate that disturbances in the Hippo pathway may contribute to HNSCC carcinogenesis and progression.

Hippo Pathway Alterations in Head and Neck Squamous Cell Carcinoma




Figure 3. Hippo Pathway Alterations in Head and Neck Squamous Cell Carcinoma. OncoPrint illustration of the 13 most frequently altered Hippo pathway associated genes in HNSCC [76,77]. Genes are listed in accordance with the HUGO gene nomenclature committee (HGNC, www.genenames.org (accessed on 31 March 2022)): *WWTR1* denotes *TAZ*, *STK3* denotes *MST2*.

8. YAP/TAZ Activation in HNSCC

HNSCC ranks among the malignancies in which YAP and TAZ amplification is most frequently observed [15]. Together YAP and TAZ are amplified in 19% of HNSCC, suggesting that a subset of these tumors are dependent on YAP/TAZ hyperactivation. Accordingly, a genome-wide CRISPR-Cas9-based inactivation screen identified dependencies on YAP or TAZ in 13 of 21 (62%) of HNSCC cell lines [78]. Interestingly, YAP/TAZ non-dependent cell lines were found to be sensitive to combined YAP and TAZ knockout, suggesting that

these cell lines could compensate for either YAP or TAZ loss via its cognate paralog [78]. Consistent with this notion, others have shown compensatory upregulation of TAZ upon YAP knockdown and vice versa [79]. Taken together, these findings demonstrate the translationally important insights that a large fraction of HNSCC display a dependency on YAP and/or TAZ, and that the vast majority of HNSCC is susceptible to combined YAP and TAZ inactivation.

9. Mechanisms of YAP/TAZ Activation in HNSCC

9.1. *FAT1: A Membrane-Associated Proto-Cadherin Assembling the Hippo Signalome*

Although dysregulation of the Hippo pathway occurs frequently in multiple human malignancies, alterations in the canonical core Hippo kinases are rarely observed. In contrast, with an alteration rate of nearly 30%, *FAT1* mutation constitutes one of the most frequent mutations in HNSCC [75]. Inactivating *FAT1* mutations, primarily in the form of homozygous deletions, but also in the form of protein-truncating nonsense mutations, strongly suggest that *FAT1* functions as a tumor suppressor [75,80,81].

Under physiological conditions, *FAT1* serves as a membrane-associated scaffold to organize the activated core Hippo signaling complex (signalome). Through loss of function, ectopic expression, and protein interaction experiments, *TAOK1/2/3* were demonstrated to represent the upstream kinases triggered by *FAT1* to activate the core Hippo complex [75]. In this context, the *FAT1* intracellular domain served to assemble the multimeric Hippo core signalome consisting of phospho-MST1 (p-MST1), p-MST2, p-SAV1, p-LATS1, and p-MOB1, culminating in YAP phosphorylation. The degree to which Hippo-mediated YAP phosphorylation is dependent upon *FAT1* is underscored by the functional loss of *FAT1*, which results in the disassembly of the Hippo signalome with consequent YAP activation, nuclear localization, and activation of YAP-mediated proliferative, survival, and tumorigenic transcriptional programs. These mechanistic observations were validated using cell-based functional assays that demonstrated *FAT1* expression abrogated YAP-activated transcription and cell proliferation, which was reversed upon co-expression of a Hippo-insensitive YAP mutant [75]. This study was the first to mechanistically link *FAT1* disruption with Hippo signaling disruption and uncontrolled YAP activation. Interestingly, *FAT1* mutation has been identified in carcinogen-induced models of HNSCC, potentially linking carcinogen-induced mutation and Hippo pathway perturbation as mediators of HPV-negative HNSCC initiation [82]. *FAT2*, *FAT3*, and *FAT4* are also recurrently altered in human HNSCC and in carcinogen-induced murine models of HNSCC [82,83]. However, the biological significance of these alterations remains to be examined [84]. While inactivating *FAT1* mutations are uncommon in HPV-positive HNSCC [85], preliminary analyses suggest that Hippo pathway perturbation and YAP/TAZ activation are also widespread in HPV-positive HNSCC (not shown), thus representing an area of active investigation.

9.2. *FAT1-Independent Mechanisms of Oncogenic Hippo Pathway Perturbation in HNSCC*

Independent of *FAT1* mutation, YAP activation is a prevalent feature of HNSCC. Epidermal growth factor receptor (EGFR) activation also represents a common event in HNSCC that is correlated with aggressive disease [86,87]. Recent studies have described a series of mechanisms through which EGFR and receptor tyrosine kinase downstream signaling cascades via RAS-MAPK and phosphoinositide-3-kinase (PI3K) can drive oncogenic YAP activation.

Amplification and gain of function mutations in *PIK3CA* result in the hyperactivation of its gene product PI3K and PI3K signaling pathway activation in HNSCC. PI3K signaling has been shown to induce nuclear YAP localization and YAP-target transcription in response to EGFR or GPCR agonists. Demonstrating strict signaling through PI3K and PDK1, this response was attenuated by PI3K and PDK1 inhibitors and siRNA mediated knockdown. Mechanistically, in cell contact-inhibited conditions, PDK1 binds to MST1 and LATS1 through SAV1, enabling Hippo activation and resulting in YAP phosphorylation and cytoplasmic retention, and cellular growth arrest. In the presence of growth factors or

constitutive PI3K signaling, PDK1 is recruited to the plasma membrane, resulting in the dissociation of the MST1:SAV1:LATS1 complex, YAP nuclear accumulation, and cell cycle entry [88].

More recently, EGFR has been shown to activate YAP/TAZ independently of PI3K through the direct phosphorylation of MOB1A in HNSCC cells [44]. EGFR phosphorylates novel MOB1A tyrosine residues in the presence of epidermal growth factor, resulting in reductions in p-LATS1/2 and p-YAP, triggering nuclear translocation of YAP and activation of YAP-mediated transcription programs. Furthermore, inhibition of EGFR in HNSCC cells with erlotinib was shown to be sufficient in abrogating YAP activation and the expression of YAP-mediated transcriptional programs. While further studies are required to delineate the mechanism by which EGFR-mediated MOB1A phosphorylation prevents LATS1 activation, this study unveiled a novel, therapeutically actionable regulatory signaling node by which multiple receptors and non-receptor tyrosine kinases may converge with the Hippo pathway to control YAP/TAZ activity [44].

Disruption in core Hippo signaling has been shown to induce HNSCC in model systems. Genetic deletion of *Mob1a* and *Mob1b* in murine lingual epithelia led to rapid squamous cell carcinoma. Consistent with the canonical Hippo core signaling model, knockout of *Mob1a/b* in tongue epithelia resulted in diminished LATS1 but not MST1 protein, increased nuclear YAP, and upregulation in YAP target genes [89]. Much remains to be understood about core Hippo signaling and the functions of MOB1 in YAP/TAZ regulation. As illustrated in the setting of *Mob1a/Mob1b* knockout in tongue epithelia, knockout of *Yap* prevented carcinogenesis induced by *Mob1a/b* deletion, but knockout of *Taz* in the same context resulted in more aggressive SCC with more invading lesions [89]. While conditional deletion of *Mob1a/b* suggests that disruption of these core Hippo complex proteins quickly leads to carcinogenesis, *Mob1a/b* can also contribute to signaling cascades beyond Hippo. For example, *Mob1a* and *Mob1b* stimulate the activity of non-Hippo kinases including STK38 (NDR1) and STK28L (NDR2) [90]. While NDR1/2 have been implicated in Hippo signaling and reported to phosphorylate YAP [91], NDR1 also serves to attenuate mitogen activated kinase signaling as a negative regulator of MAP3K1/2 [92]. Indeed, collectively NDR1/2 exert pleiotropic potentially proto-oncogenic influences on cell cycle progression, apoptosis, stress signaling, and autophagy [93]. Exploring the complex interactions across Hippo and other signaling cascades may clarify seemingly paradoxical effects observed upon the genetic depletion of kinase-regulatory scaffolds, such as *Mob1a/b*.

10. Consequences YAP/TAZ Activation in HNSCC

10.1. Cancer Stemness

Chromosome 3q25-26 is a frequently amplified locus in HNSCC that harbors multiple cancer-associated genes including *WWTR1* (*TAZ*), *PIK3CA*, and *SOX2*. Co-occurrence of 3q25-26 amplification and *TP53* mutation is associated with poor prognosis in HNSCC [94]. Interestingly, a TAZ:TEAD4 complex has been shown to co-activate *SOX2* transcription in HNSCC. In this context, *SOX2* expression was found sufficient to promote cancer stem cell marker expression, tumor cell self-renewal in vitro, and tumor growth in vivo [95]. Importantly, knockdown of TAZ diminished these phenotypes and exogenous expression of *SOX2* upon TAZ knockdown was sufficient to rescue them. Together, these findings show that TAZ- and TEAD4-mediated coactivation of *SOX2* expression is sufficient to induce stemness programs in HNSCC and offer the possibility that TAZ activation may mediate transcriptional programs that lead to the poor prognosis associated with 3q25-26 copy gain. In line with these findings, an independent study found that TAZ activation promotes migration, invasion, and survival by an epithelial to mesenchymal transition-like program in HNSCC cells, which in turn promotes cancer stem cell maintenance and expansion [96].

The recurrently amplified segment of chromosome 3q also harbors two genes that are frequently co-amplified in HNSCC: *TP63*, a key regulator of epidermal cell differentiation and proliferation [97], and *ACTL6A*, a subunit of the SWI/SNF ATP-dependent chromatin remodeling complexes [98]. Interestingly, p63 forms a complex with *ACTL6A* and other

SWI/SNF subunits in HNSCC to control a stem-like transcriptional program that enhances the regenerative potential of HNSCC cells *in vitro*, and promotes a pro-tumorigenic proliferative, undifferentiated cancer cell state *in vivo*. Importantly, p63 and ACTL6A were found to directly repress transcription of *WWC1* [99]. The gene product of *WWC1*, Kibra, is a tumor suppressor that promotes Hippo pathway activation [100,101], thereby releasing Hippo-mediated inhibition of YAP/TAZ. Indeed, depletion of p63 or ACTL6A, increased Kibra expression, increased p-YAP, depressed nuclear translocation of YAP, and diminished HNSCC regenerative potential *in vitro* [99].

10.2. Tumor Progression and Poor Prognosis

Progressively increased YAP activation is a feature of oncogenic progression in diverse malignancies [102]. In the squamous epithelia of the upper aerodigestive tract, physiologically nuclear YAP is restricted to the basal epidermis [75,103]. The extent and degree of nuclear YAP have been shown to progressively increase with worsening histological severity in oral premalignant lesions and culminate with diffuse, strong nuclear YAP expression in the majority of cells in HNSCC. Furthermore, the frequency of nuclear YAP-positive tumor cells also increases with worsening histological grade in HNSCC [75,79]. Array-based transcriptome profiling upon YAP/TAZ knockdown in HNSCC cell lines has elucidated YAP/TAZ-mediated transcription programs in HNSCC. The resultant YAP/TAZ-regulated gene signature, defined as the set of transcripts downregulated upon YAP/TAZ knockdown, showed enrichment for stemness, self-renewal, cell cycle progression, and invasion programs [79]. Consistent with these findings, it has also been shown that nuclear YAP and TAZ in HNSCC are enriched at the tumor invasive front [104,105]. In addition, increased nuclear YAP expression in primary tumor specimens has been associated with lymph node metastasis, further suggesting that YAP may play a role in driving invasion and metastatic programs [105]. In line with these findings, TAZ activation was also shown to be a prevalent feature in HNSCC cell lines and an independent prognostic factor for disease-free and overall survival in patients with tongue HNSCC [106].

Whether cancer associated mutations modify prognosis or therapeutic sensitivity are key questions that may shed insight into mechanisms of tumor initiation and progression, and aid in the identification of prognostic, diagnostic, and therapeutic biomarkers. In this regard, the potential roles of YAP/TAZ on prognosis and other clinicopathologic features in HNSCC have been evaluated. YAP copy number alteration (CNA) is observed in 8% of HNSCC. While YAP amplification is associated with increased YAP transcript abundance, augmented YAP expression is often observed in HNSCC in the absence of CNA [107]. Post-translational signaling cascades regulate YAP activation; therefore, YAP activity is likely not directly related to its transcriptional expression levels. Eun and colleagues interrogated the Cancer Genome Atlas (TCGA) database to identify transcripts correlated with YAP transcript expression and CNA in order to develop a gene expression signature for YAP activation [107]. This YAP activation signature was found to stratify prognosis with regard to disease-free survival, disease-specific survival, and overall survival in four independent patient cohorts. Importantly, the YAP activation signature stratified survival after multivariable correction for confounding clinical factors known to be associated with survival (age, tumor classification, nodal classification, TNM staging group, and anatomic site) [107].

Analyses of clinical data-linked, genome-wide databases have identified interactions between PIK3CA and YAP activation in HNSCC and demonstrated that these interactions may be associated with survival outcomes. While neither mutation nor CNA in PIK3CA was associated with recurrence-free survival (RFS), PIK3CA mRNA expression was found to be associated with RFS in TCGA and an independent dataset on single and multivariable analyses [108]. Consistent with mechanistic models in which PIK3CA activation induces downstream YAP dephosphorylation and nuclear translocation to drive YAP-mediated transcription programs, HNSCC tumor samples with high PIK3CA expression displayed lower abundances of p-YAP and PIK3CA-high tumors expressed transcriptional programs

enriched for YAP/TAZ target genes [108]. These provide translational relevance to the mechanistic studies linking PIK3CA activity to YAP/TAZ activation, suggest that the PIK3CA-YAP axis may drive aggressive forms of HNSCC, and provide a strong rationale to target YAP in PIK3CA^{high} HNSCC.

10.3. Therapeutic Resistance

Combined with radiotherapy and surgical resection, cisplatin-based chemotherapy is a mainstay of curative-intent therapy for HNSCC [109]. Limited evidence suggests that short interfering RNA-mediated YAP-knockdown re-sensitizes cisplatin-resistant HNSCC cell lines to cisplatin. These findings suggest that YAP may be considered a potential therapeutic target for cisplatin-resistant HNSCC [110]. Using a similar line of experimentation, an independent group identified a ribosome-binding protein that mediates the interaction between the ribosome and the endoplasmic reticulum membrane, RRBP1, as a mediator of cisplatin resistance in HNSCC by augmenting YAP expression. In this setting, the use of a putative RRBP1 inhibitor, Radelozid, diminished YAP expression and sensitized HNSCC cells to cisplatin in both in vitro and in vivo assays [111]. In addition, TAZ overexpression has been shown to enhance resistance while YAP or TAZ knockdown sensitizes HNSCC cell lines to cisplatin and fluorouracil [96,112].

More recently, precision therapeutic targeting of the MAPK pathway, which is commonly activated in HNSCC and is associated with more aggressive tumor growth, nodal metastasis, and recurrence, has been evaluated in clinical trials [113–115]. In a window-of-opportunity trial in previously untreated HNSCC patients, the small molecule MEK inhibitor trametinib was shown to inhibit the MAPK pathway in 33% of patients, as evaluated by tumor p-ERK abundance, and to result in clinical tumor response rates in 65% of patients [116]. Given that single-modality targeting of MAPK signaling has not shown durable efficacy in a wide variety of tumor types [117], follow up studies have explored mechanisms of trametinib resistance in HNSCC that could lead to multimodal precision therapeutics with durable efficacy. In this regard, trametinib-resistant HNSCC cell lines were generated by culturing cells in sequentially increasing doses of trametinib. The resultant cells demonstrated at least 10⁵-fold increased resistance to trametinib and elevated YAP activity as measured by transcriptional reporter assays and upregulation of canonical YAP-target genes. In addition, trametinib-treated patient-derived xenografts that escaped growth inhibition were found to have 15-fold greater abundances of unphosphorylated YAP protein and upregulated YAP-target genes. Accordingly, combining trametinib with verteporfin, which inhibits YAP signaling, showed synergistic effects. These results highlight the potential importance of YAP activation in mediating resistance to MAPK pathway inhibition and suggest YAP inhibition as a potential strategy to enhance the efficacy of MAPK pathway inhibition in patients with HNSCC [118].

11. YAP/TAZ Activation Exposes HNSCC Vulnerabilities and Therapeutic Opportunities

Accumulating evidence demonstrating YAP and TAZ as oncogenic effectors and essential cancer dependencies in HNSCC supports the development of novel oncotherapeutics against YAP/TAZ [17,18]. However, therapeutic targeting of transcription factors remains a major challenge. Beyond YAP and TAZ, numerous cancer-associated transcription factors have emerged as promising therapeutic targets [119]. Yet the development of specific small molecule therapeutics against transcription factors has been hampered by hurdles related to the transcription factors not typically possessing enzymatic activities and practical challenges of disrupting protein:protein and protein:nucleic acid interactions [119].

The requirement for YAP/TAZ to interact with TEAD family DNA binding proteins present an opportunity for its inhibition. An in vitro functional screen in mammalian cells for small molecule inhibitors of YAP:TEAD based transcriptional transactivation identified three porphyrin derivatives protoporphyrin IX, hematoporphyrin, and verteporfin as inhibitors of YAP-induced transcription [120]. Coincidentally, an independent screen identified these same three porphyrins as disruptors of YAP:TEAD interaction in *Drosophila*.

Further studies validated verteporfin as a strong inhibitor of YAP:TEAD interaction [120]. Verteporfin is an FDA-approved photosensitizer used in photodynamic therapy for the treatment of age-related macular degeneration, suggesting verteporfin exerts cellular effects beyond the inhibition of YAP:TEAD interactions (Figure 4) [121]. Despite being studied for the past decade as a YAP inhibitor, structural mechanistic details about its interaction with YAP/TAZ remain unclear, and its effects on cellular targets other than YAP/TAZ, including autophagosome inhibition, suggesting that verteporfin constitutes a nonspecific YAP/TAZ inhibitor [122].




Figure 4. Targeting Hippo and YAP/TAZ. Therapeutic agents promoting Hippo activation or YAP/TAZ inhibition are shown in red. Grey arrows and molecules indicate inhibition of downstream processes. Cetuximab-mediated EGFR inhibition, Alpelisib-mediated PI3K inhibition, Dasatinib-mediated SRC inhibition, Defactinib and IN10018-mediated FAK inhibition, and Trametinib-mediated MEK inhibition relieve Hippo-inhibitory inputs and enable Hippo signaling to inhibit YAP/TAZ. Tankyrase inhibitors prevent proteolytic degradation of AMOT, enabling AMOT to activate Hippo signaling. Small molecule TEAD inhibitors (smTEADi) prevent YAP/TAZ:TEAD interaction by inhibiting TEAD autopalmitylation. Verteporfin inhibits YAP/TAZ:TEAD interaction [11,116,120,123–128].

Further study of the YAP/TAZ:TEAD interaction has revealed a unique mechanism through which YAP/TAZ and TEAD family proteins interact to co-activate transcription and has unveiled a novel opportunity for pharmacologic inhibition. YAP/TAZ and TEAD complex formation require an autopalmitylation event in which TEAD catalyzes the covalent attachment of a palmitate fatty acid to itself. TEAD autopalmitylation is both necessary for YAP/TAZ:TEAD complex formation and YAP/TAZ-mediated transcriptional co-activation [129]. Small molecule inhibitors of TEAD autopalmitylation have recently been demonstrated to bind TEAD proteins and prevent TEAD autopalmitylation, disrupt YAP/TAZ interaction with TEAD proteins, diminish YAP/TAZ:TEAD transcriptional co-activation, downregulate YAP/TAZ:TEAD target transcripts, and inhibit in vivo tumor growth of *NF2*-deficient cancer cell lines (Figure 4) [123]. Whether TEAD autopalmitylation inhibitors show activity against YAP-activated HNSCC remains an open question and an area of active investigation.

Numerous cellular mechanisms regulate YAP/TAZ activity. Thus, YAP/TAZ inhibition could be achieved through a variety of therapeutic avenues beyond the disruption of YAP/TAZ:TEAD interactions. As described earlier in this review, the GPCR-PKA signaling axis modulates Hippo-YAP/TAZ activity. GPCRs represent one of the most frequently targeted protein classes, with small molecule and peptide drugs designed to target essentially every type of GPCR either approved for clinical use or in clinical development [52,130]. Pharmacological inhibition of $G_{12/13}$ or $G_{q/11}$, or pharmacological activation of G_s could achieve downstream YAP/TAZ inhibition. Attempting to target the Hippo pathway far upstream of YAP/TAZ at plasma membrane bound receptors, however, could result in unforeseen effects [131,132].

PKA may represent another therapeutic target in GPCR-PKA-mediated regulation of the Hippo pathway. Interestingly, PKA inhibition via phosphatase PP2A activation has shown antineoplastic activity against models of small cell carcinoma [133]. Given that PP2A drives YAP/TAZ activation, the therapeutic use of PP2A phosphatase activators is unlikely to be beneficial in the treatment of HNSCC. However, drugs that target and inactivate PP2A may prove beneficial in the treatment of HNSCC. PP2A inhibitors are in current development and have shown efficacy against a variety of YAP-activated tumor types [134,135].

The interaction of β -catenin and YAP/TAZ also presents a potential therapeutically actionable opportunity. Wnt/ β -catenin signaling has independently been associated with tumor initiation and progression and, as a result, multiple inhibitors of this pathway have been developed [136]. Given its role in downregulating β -catenin activity, the β -catenin destruction complex has been a focus for therapeutic intervention with the development of tankyrase inhibitors [132,133]. Tankyrase (TNKS) interacts with and degrades the β -catenin destruction complex component Axin via ubiquitin-mediated proteasomal degradation [137,138]. Tankyrase inhibitors and other compounds that stabilize Axin have been shown to inhibit both YAP/TAZ and β -catenin activity through the cytoplasmic retention of YAP/TAZ and subsequent restoration of destruction complex activity (Figure 4) [18,139]. In this manner, tankyrase inhibitors promote YAP/TAZ inhibition by the β -catenin destruction complex. More recently, tankyrase inhibitors have been shown to also exert a more direct effect on the Hippo pathway by stabilizing AMOT family proteins, which promote the cytoplasmic retention of YAP/TAZ and prevent YAP/TAZ induced transcriptional programs [124,140].

12. Conclusions

Since its discovery, intensive investigation of the Hippo pathway and its downstream effectors has considerably advanced our understanding of this dynamic signal transduction circuit and its ability to control normal tissue growth and cancer initiation and progression, therapy resistance, and metastatic spread. Inhibitors of YAP/TAZ activity, including newly developed TEAD autopalmitylation inhibitors, hold significant promise as antineoplastic agents in multiple cancer types, including HNSCC. Given YAP and TAZ's pleiotropic roles in tumor cell proliferation, cancer stem cell self-renewal and metastatic potential, YAP/TAZ inhibition is likely to display single agent activity in multiple cancer types that are dependent on YAP/TAZ function for tumor cell growth and survival. Yet the true potential of YAP/TAZ signaling inhibitors may be achieved by the combination with immune checkpoint inhibition, agents targeting additional oncogenic pathways, or the use of multimodal precision therapies co-targeting YAP/TAZ and their intrinsic and compensatory resistance pathways, thereby achieving durable cancer remission.

Author Contributions: Conceptualization, F.F. and J.S.G.; methodology, F.F. and S.I.R.; validation, F.F., S.I.R. and J.S.G.; formal analysis, F.F.; investigation, F.F. & S.I.R.; data curation, F.F.; writing—original draft preparation, F.F., S.I.R., P.Y.A.Q., A.N.M.-M. and J.S.G.; writing—review and editing, F.F., S.I.R., P.Y.A.Q., A.N.M.-M. and J.S.G.; visualization, F.F.; supervision, J.S.G.; project administration, F.F. and J.S.G.; funding acquisition, F.F., S.I.R., P.Y.A.Q., A.N.M.-M. and J.S.G. All authors have read and agreed to the published version of the manuscript.

Funding: F.F. receives funding from NIH T32 DC000028 and Stand Up To Cancer. S.I.R. receives funding from NIH T32 AI007036. P.Y.A.Q. and A.N.M.-M. receive funding from NIH R25CA221779. J.S.G. receives funding from NIH U01 DE028227, NIH R01 DE026870, NIH R01 DE026644, NIH R01 CA247551, NIH R01 DE030497, and Stand Up To Cancer.

Acknowledgments: The Graphical Abstract and Figures 1, 2 and 4 were created in BioRender.com (accessed on 1 April 2022).

Conflicts of Interest: J.S.G. is consultant for Domain Therapeutics, Pangea Therapeutics, and io9, and founder of Kadima Pharmaceuticals, outside the submitted work. No disclosures were reported by the other authors.

Abbreviations

| | |
|-----------|--|
| MST1/2 | Mammalian STE20-like protein kinase 1/2 (also known as STK4/3) |
| SAV1 | Protein salvador homolog 1 |
| LATS1/2 | Large tumor suppressor homolog 1/2 |
| MOB1A/B | Mps one binder kinase activator-like 1A/B |
| YAP | Yes-associated protein 1 (also known as YAP1) |
| TAZ | Transcriptional coactivator with PDZ-binding motif (also known as WWTR1) |
| TEAD | Transcriptional enhancer factor TEF-1/2/3/4 (also known as TEAD1/2/3/4) |
| TAOK1/2/3 | Thousand and one amino acid protein kinase 1/2/3 |
| FRMD6 | FERM domain-containing protein 6 (also known as Willin) |
| RASSF1A | Ras association domain-containing protein 1A |
| WWC1 | WW domain-containing protein 1 (also known KIBRA) |
| AMOT | Angiomotin |
| NF2 | neurofibromin 2 (also known as Merlin) |
| AJUBA | LIM domain-containing protein ajuba (also known as JUB) |
| STRIPAK | Striatin-interacting phosphatase and kinase |
| FAK | focal adhesion kinase 1 (also known as PTK2) |
| SRC | Proto-oncogene tyrosine-protein kinase Src |
| PI3K | phosphoinositol-3 kinase |
| PDK1 | 3-phosphoinositide-dependent protein kinase 1 |

References

1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. *Int. J. Cancer* **2021**, *149*, 778–789. [[CrossRef](#)] [[PubMed](#)]
2. Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2020. Available online: <https://gco.iarc.fr/today> (accessed on 16 March 2022).
3. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **2021**, *71*, 209–249. [[CrossRef](#)] [[PubMed](#)]
4. Marur, S.; Forastiere, A.A. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. *Mayo Clin. Proc.* **2016**, *91*, 386–396. [[CrossRef](#)]
5. Johnson, D.E.; Burtness, B.; Leemans, C.R.; Lui, V.W.Y.; Bauman, J.E.; Grandis, J.R. Head and neck squamous cell carcinoma. *Nat. Rev. Dis. Primer* **2020**, *6*, 92. [[CrossRef](#)] [[PubMed](#)]
6. Wong, K.C.W.; Hui, E.P.; Lo, K.-W.; Lam, W.K.J.; Johnson, D.; Li, L.; Tao, Q.; Chan, K.C.A.; To, K.-F.; King, A.D.; et al. Nasopharyngeal carcinoma: An evolving paradigm. *Nat. Rev. Clin. Oncol.* **2021**, *18*, 679–695. [[CrossRef](#)]
7. Pulte, D.; Brenner, H. Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. *Oncologist* **2010**, *15*, 994–1001. [[CrossRef](#)] [[PubMed](#)]
8. Abrahão, R.; Anantharaman, D.; Gaborieau, V.; Abedi-Ardekani, B.; Lagiou, P.; Lagiou, A.; Ahrens, W.; Holcatova, I.; Betka, J.; Merletti, F.; et al. The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in Europe: The ARCAGE study. *Int. J. Cancer* **2018**, *143*, 32–44. [[CrossRef](#)]
9. Brouwer, A.F.; He, K.; Chinn, S.B.; Mondul, A.M.; Chapman, C.H.; Ryser, M.D.; Banerjee, M.; Eisenberg, M.C.; Meza, R.; Taylor, J.M.G. Time-varying survival effects for squamous cell carcinomas at oropharyngeal and nonoropharyngeal head and neck sites in the United States, 1973–2015. *Cancer* **2020**, *126*, 5137–5146. [[CrossRef](#)]
10. Ferris, R.L.; Blumenschein, G.; Fayette, J.; Guigay, J.; Colevas, A.D.; Licitra, L.; Harrington, K.; Kasper, S.; Vokes, E.E.; Even, C.; et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N. Engl. J. Med.* **2016**, *375*, 1856–1867. [[CrossRef](#)]

11. Burtneß, B.; Harrington, K.J.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G.; Psyrrí, A.; Basté, N.; Neupane, P.; Bratland, Å.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. *Lancet Lond. Engl.* **2019**, *394*, 1915–1928. [[CrossRef](#)]
12. Ma, S.; Meng, Z.; Chen, R.; Guan, K.-L. The Hippo Pathway: Biology and Pathophysiology. *Annu. Rev. Biochem.* **2019**, *88*, 577–604. [[CrossRef](#)] [[PubMed](#)]
13. Zheng, Y.; Pan, D. The Hippo Signaling Pathway in Development and Disease. *Dev. Cell* **2019**, *50*, 264–282. [[CrossRef](#)] [[PubMed](#)]
14. Harvey, K.F.; Zhang, X.; Thomas, D.M. The Hippo pathway and human cancer. *Nat. Rev. Cancer* **2013**, *13*, 246–257. [[CrossRef](#)]
15. Wang, Y.; Xu, X.; Maglic, D.; Dill, M.T.; Mojumdar, K.; Ng, P.K.-S.; Jeong, K.J.; Tsang, Y.H.; Moreno, D.; Bhavana, V.H.; et al. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep.* **2018**, *25*, 1304–1317.e5. [[CrossRef](#)]
16. Pearson, J.D.; Huang, K.; Pacal, M.; McCurdy, S.R.; Lu, S.; Aubry, A.; Yu, T.; Wadosky, K.M.; Zhang, L.; Wang, T.; et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer Cell* **2021**, *39*, 1115–1134.e12. [[CrossRef](#)]
17. Calses, P.C.; Crawford, J.J.; Lill, J.R.; Dey, A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. *Trends Cancer* **2019**, *5*, 297–307. [[CrossRef](#)] [[PubMed](#)]
18. Zanonato, F.; Battilana, G.; Cordenonsi, M.; Piccolo, S. YAP/TAZ as therapeutic targets in cancer. *Curr. Opin. Pharmacol.* **2016**, *29*, 26–33. [[CrossRef](#)]
19. Justice, R.W.; Zilian, O.; Woods, D.F.; Noll, M.; Bryant, P.J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. *Genes Dev.* **1995**, *9*, 534–546. [[CrossRef](#)]
20. Bae, S.J.; Ni, L.; Osinski, A.; Tomchick, D.R.; Brautigam, C.A.; Luo, X. SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK. *eLife* **2017**, *6*, e30278. [[CrossRef](#)]
21. Callus, B.A.; Verhagen, A.M.; Vaux, D.L. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. *FEBS J.* **2006**, *273*, 4264–4276. [[CrossRef](#)]
22. Meng, Z.; Moroishi, T.; Mottier-Pavie, V.; Plouffe, S.W.; Hansen, C.G.; Hong, A.W.; Park, H.W.; Mo, J.-S.; Lu, W.; Lu, S.; et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. *Nat. Commun.* **2015**, *6*, 8357. [[CrossRef](#)]
23. Plouffe, S.W.; Meng, Z.; Lin, K.C.; Lin, B.; Hong, A.W.; Chun, J.V.; Guan, K.-L. Characterization of Hippo Pathway Components by Gene Inactivation. *Mol. Cell* **2016**, *64*, 993–1008. [[CrossRef](#)] [[PubMed](#)]
24. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* **2007**, *21*, 2747–2761. [[CrossRef](#)]
25. Totaro, A.; Panciera, T.; Piccolo, S. YAP/TAZ upstream signals and downstream responses. *Nat. Cell Biol.* **2018**, *20*, 888–899. [[CrossRef](#)]
26. Chen, Q.; Zhang, N.; Xie, R.; Wang, W.; Cai, J.; Choi, K.-S.; David, K.K.; Huang, B.; Yabuta, N.; Nojima, H.; et al. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. *Genes Dev.* **2015**, *29*, 1285–1297. [[CrossRef](#)]
27. Moroishi, T.; Park, H.W.; Qin, B.; Chen, Q.; Meng, Z.; Plouffe, S.W.; Taniguchi, K.; Yu, F.-X.; Karin, M.; Pan, D.; et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. *Genes Dev.* **2015**, *29*, 1271–1284. [[CrossRef](#)]
28. Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.-Y.; Guan, K.-L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes Dev.* **2010**, *24*, 72–85. [[CrossRef](#)] [[PubMed](#)]
29. Liu, C.-Y.; Zha, Z.-Y.; Zhou, X.; Zhang, H.; Huang, W.; Zhao, D.; Li, T.; Chan, S.W.; Lim, C.J.; Hong, W.; et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. *J. Biol. Chem.* **2010**, *285*, 37159–37169. [[CrossRef](#)]
30. Zeng, Q.; Hong, W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. *Cancer Cell* **2008**, *13*, 188–192. [[CrossRef](#)]
31. Piccolo, S.; Dupont, S.; Cordenonsi, M. The biology of YAP/TAZ: Hippo signaling and beyond. *Physiol. Rev.* **2014**, *94*, 1287–1312. [[CrossRef](#)] [[PubMed](#)]
32. Misra, J.R.; Irvine, K.D. The Hippo Signaling Network and Its Biological Functions. *Annu. Rev. Genet.* **2018**, *52*, 65–87. [[CrossRef](#)] [[PubMed](#)]
33. Yu, F.-X.; Zhao, B.; Guan, K.-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* **2015**, *163*, 811–828. [[CrossRef](#)] [[PubMed](#)]
34. Zhang, N.; Bai, H.; David, K.K.; Dong, J.; Zheng, Y.; Cai, J.; Giovannini, M.; Liu, P.; Anders, R.A.; Pan, D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Dev. Cell* **2010**, *19*, 27–38. [[CrossRef](#)] [[PubMed](#)]
35. Zhou, D.; Zhang, Y.; Wu, H.; Barry, E.; Yin, Y.; Lawrence, E.; Dawson, D.; Willis, J.E.; Markowitz, S.D.; Camargo, F.D.; et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, E1312–E1320. [[CrossRef](#)]
36. Choi, W.; Kim, J.; Park, J.; Lee, D.-H.; Hwang, D.; Kim, J.-H.; Ashktorab, H.; Smoot, D.; Kim, S.-Y.; Choi, C.; et al. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. *Cancer Res.* **2018**, *78*, 3306–3320. [[CrossRef](#)] [[PubMed](#)]

37. Couzens, A.L.; Knight, J.D.R.; Kean, M.J.; Teo, G.; Weiss, A.; Dunham, W.H.; Lin, Z.-Y.; Bagshaw, R.D.; Sicheri, F.; Pawson, T.; et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. *Sci. Signal.* **2013**, *6*, rs15. [[CrossRef](#)]
38. Praskova, M.; Khoklatchev, A.; Ortiz-Vega, S.; Avruch, J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. *Biochem. J.* **2004**, *381*, 453–462. [[CrossRef](#)]
39. Zheng, Y.; Liu, B.; Wang, L.; Lei, H.; Pulgar Prieto, K.D.; Pan, D. Homeostatic Control of Hpo/MST Kinase Activity through Autophosphorylation-Dependent Recruitment of the STRIPAK PP2A Phosphatase Complex. *Cell Rep.* **2017**, *21*, 3612–3623. [[CrossRef](#)]
40. Angus, L.; Moleirinho, S.; Herron, L.; Sinha, A.; Zhang, X.; Niestrata, M.; Dholakia, K.; Prystowsky, M.B.; Harvey, K.F.; Reynolds, P.A.; et al. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. *Oncogene* **2012**, *31*, 238–250. [[CrossRef](#)]
41. Li, Y.; Zhou, H.; Li, F.; Chan, S.W.; Lin, Z.; Wei, Z.; Yang, Z.; Guo, F.; Lim, C.J.; Xing, W.; et al. Angiotensin binding-induced activation of Merlin/NF2 in the Hippo pathway. *Cell Res.* **2015**, *25*, 801–817. [[CrossRef](#)]
42. Furukawa, K.T.; Yamashita, K.; Sakurai, N.; Ohno, S. The Epithelial Circumferential Actin Belt Regulates YAP/TAZ through Nucleocytoplasmic Shuttling of Merlin. *Cell Rep.* **2017**, *20*, 1435–1447. [[CrossRef](#)] [[PubMed](#)]
43. Reddy, B.V.V.G.; Irvine, K.D. Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. *Dev. Cell* **2013**, *24*, 459–471. [[CrossRef](#)] [[PubMed](#)]
44. Ando, T.; Arang, N.; Wang, Z.; Costea, D.E.; Feng, X.; Goto, Y.; Izumi, H.; Gilardi, M.; Ando, K.; Gutkind, J.S. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. *Commun. Biol.* **2021**, *4*, 1237. [[CrossRef](#)] [[PubMed](#)]
45. Yu, F.-X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.; Yuan, H.; Tumaneng, K.; Li, H.; et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* **2012**, *150*, 780–791. [[CrossRef](#)] [[PubMed](#)]
46. Kim, M.; Kim, M.; Lee, S.; Kuninaka, S.; Saya, H.; Lee, H.; Lee, S.; Lim, D.-S. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. *EMBO J.* **2013**, *32*, 1543–1555. [[CrossRef](#)]
47. Lee, J.-H.; Kim, T.-S.; Yang, T.-H.; Koo, B.-K.; Oh, S.-P.; Lee, K.-P.; Oh, H.-J.; Lee, S.-H.; Kong, Y.-Y.; Kim, J.-M.; et al. A crucial role of WW45 in developing epithelial tissues in the mouse. *EMBO J.* **2008**, *27*, 1231–1242. [[CrossRef](#)]
48. Feng, X.; Degese, M.S.; Iglesias-Bartolome, R.; Vaque, J.P.; Molinolo, A.A.; Rodrigues, M.; Zaidi, M.R.; Ksander, B.R.; Merlino, G.; Sodhi, A.; et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell* **2014**, *25*, 831–845. [[CrossRef](#)]
49. Yu, F.-X.; Luo, J.; Mo, J.-S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* **2014**, *25*, 822–830. [[CrossRef](#)]
50. Feng, X.; Arang, N.; Rigracciolo, D.C.; Lee, J.S.; Yeerna, H.; Wang, Z.; Lubrano, S.; Kishore, A.; Pachter, J.A.; König, G.M.; et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell* **2019**, *35*, 457–472.e5. [[CrossRef](#)]
51. Iglesias-Bartolome, R.; Torres, D.; Marone, R.; Feng, X.; Martin, D.; Simaan, M.; Chen, M.; Weinstein, L.S.; Taylor, S.S.; Molinolo, A.A.; et al. Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nat. Cell Biol.* **2015**, *17*, 793–803. [[CrossRef](#)]
52. Ramms, D.J.; Raimondi, F.; Arang, N.; Herberg, F.W.; Taylor, S.S.; Gutkind, J.S. Gαs-Protein Kinase A (PKA) Pathway Signalingopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling. *Pharmacol. Rev.* **2021**, *73*, 155–197. [[CrossRef](#)] [[PubMed](#)]
53. Azzolin, L.; Panciera, T.; Soligo, S.; Enzo, E.; Bicciato, S.; Dupont, S.; Bresolin, S.; Frasson, C.; Basso, G.; Guzzardo, V.; et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. *Cell* **2014**, *158*, 157–170. [[CrossRef](#)] [[PubMed](#)]
54. Castellone, M.D.; Teramoto, H.; Williams, B.O.; Druey, K.M.; Gutkind, J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. *Science* **2005**, *310*, 1504–1510. [[CrossRef](#)] [[PubMed](#)]
55. Fang, X.; Yu, S.X.; Lu, Y.; Bast, R.C.; Woodgett, J.R.; Mills, G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 11960–11965. [[CrossRef](#)]
56. Hino, S.; Tanji, C.; Nakayama, K.I.; Kikuchi, A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. *Mol. Cell. Biol.* **2005**, *25*, 9063–9072. [[CrossRef](#)]
57. Schlegelmilch, K.; Mohseni, M.; Kirak, O.; Pruszk, J.; Rodriguez, J.R.; Zhou, D.; Kreger, B.T.; Vasioukhin, V.; Avruch, J.; Brummelkamp, T.R.; et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. *Cell* **2011**, *144*, 782–795. [[CrossRef](#)]
58. Ibar, C.; Kirichenko, E.; Keepers, B.; Enners, E.; Fleisch, K.; Irvine, K.D. Tension-dependent regulation of mammalian Hippo signaling through LIMD1. *J. Cell Sci.* **2018**, *131*, jcs214700. [[CrossRef](#)]
59. Benham-Pyle, B.W.; Pruitt, B.L.; Nelson, W.J. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry. *Science* **2015**, *348*, 1024–1027. [[CrossRef](#)]
60. Dong, J.; Feldmann, G.; Huang, J.; Wu, S.; Zhang, N.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.; Maitra, A.; Pan, D. Elucidation of a universal size-control mechanism in Drosophila and mammals. *Cell* **2007**, *130*, 1120–1133. [[CrossRef](#)]
61. Kim, N.-G.; Koh, E.; Chen, X.; Gumbiner, B.M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 11930–11935. [[CrossRef](#)]

62. Zhao, B.; Li, L.; Lu, Q.; Wang, L.H.; Liu, C.-Y.; Lei, Q.; Guan, K.-L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. *Genes Dev.* **2011**, *25*, 51–63. [[CrossRef](#)] [[PubMed](#)]
63. Si, Y.; Ji, X.; Cao, X.; Dai, X.; Xu, L.; Zhao, H.; Guo, X.; Yan, H.; Zhang, H.; Zhu, C.; et al. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1. *Cancer Res.* **2017**, *77*, 4868–4880. [[CrossRef](#)] [[PubMed](#)]
64. Zhao, B.; Li, L.; Wang, L.; Wang, C.-Y.; Yu, J.; Guan, K.-L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. *Genes Dev.* **2012**, *26*, 54–68. [[CrossRef](#)] [[PubMed](#)]
65. Kim, N.-G.; Gumbiner, B.M. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. *J. Cell Biol.* **2015**, *210*, 503–515. [[CrossRef](#)]
66. Aragona, M.; Panciera, T.; Manfrin, A.; Giullitti, S.; Michielin, F.; Elvassore, N.; Dupont, S.; Piccolo, S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell* **2013**, *154*, 1047–1059. [[CrossRef](#)]
67. Miller, R.T. Mechanical properties of basement membrane in health and disease. *Matrix Biol. J. Int. Soc. Matrix Biol.* **2017**, *57–58*, 366–373. [[CrossRef](#)]
68. Fang, M.; Yuan, J.; Peng, C.; Li, Y. Collagen as a double-edged sword in tumor progression. *Tumour Biol. J. Int. Soc. Oncodev. Biol. Med.* **2014**, *35*, 2871–2882. [[CrossRef](#)]
69. Mouw, J.K.; Ou, G.; Weaver, V.M. Extracellular matrix assembly: A multiscale deconstruction. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 771–785. [[CrossRef](#)]
70. Fejza, A.; Camicia, L.; Poletto, E.; Carobolante, G.; Mongiat, M.; Andreuzzi, E. ECM Remodeling in Squamous Cell Carcinoma of the Aerodigestive Tract: Pathways for Cancer Dissemination and Emerging Biomarkers. *Cancers* **2021**, *13*, 2759. [[CrossRef](#)]
71. Camargo, F.D.; Gokhale, S.; Johnnidis, J.B.; Fu, D.; Bell, G.W.; Jaenisch, R.; Brummelkamp, T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. *Curr. Biol. CB* **2007**, *17*, 2054–2060. [[CrossRef](#)]
72. Zanconato, F.; Forcato, M.; Battilana, G.; Azzolin, L.; Quaranta, E.; Bodega, B.; Rosato, A.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell Biol.* **2015**, *17*, 1218–1227. [[CrossRef](#)] [[PubMed](#)]
73. Lian, I.; Kim, J.; Okazawa, H.; Zhao, J.; Zhao, B.; Yu, J.; Chinnaiyan, A.; Israel, M.A.; Goldstein, L.S.B.; Abujarour, R.; et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. *Genes Dev.* **2010**, *24*, 1106–1118. [[CrossRef](#)] [[PubMed](#)]
74. Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* **2015**, *517*, 576–582. [[CrossRef](#)] [[PubMed](#)]
75. Martin, D.; Degese, M.S.; Vitale-Cross, L.; Iglesias-Bartolome, R.; Valera, J.L.C.; Wang, Z.; Feng, X.; Yeerna, H.; Vadmal, V.; Moroishi, T.; et al. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. *Nat. Commun.* **2018**, *9*, 2372. [[CrossRef](#)]
76. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2012**, *2*, 401–404. [[CrossRef](#)]
77. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **2013**, *6*, p11. [[CrossRef](#)]
78. Chai, A.W.Y.; Yee, P.S.; Price, S.; Yee, S.M.; Lee, H.M.; Tiong, V.K.; Gonçalves, E.; Behan, F.M.; Bateson, J.; Gilbert, J.; et al. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. *eLife* **2020**, *9*, e57761. [[CrossRef](#)]
79. Hiemer, S.E.; Zhang, L.; Kartha, V.K.; Packer, T.S.; Almershed, M.; Noonan, V.; Kukuruzinska, M.; Bais, M.V.; Monti, S.; Varelas, X. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma. *Mol. Cancer Res. MCR* **2015**, *13*, 957–968. [[CrossRef](#)]
80. Morris, L.G.T.; Kaufman, A.M.; Gong, Y.; Ramaswami, D.; Walsh, L.A.; Turcan, Ş.; Eng, S.; Kannan, K.; Zou, Y.; Peng, L.; et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. *Nat. Genet.* **2013**, *45*, 253–261. [[CrossRef](#)]
81. Pastushenko, I.; Mauri, F.; Song, Y.; de Cock, F.; Meeusen, B.; Swedlund, B.; Impens, F.; Van Haver, D.; Opitz, M.; Thery, M.; et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. *Nature* **2021**, *589*, 448–455. [[CrossRef](#)]
82. Wang, Z.; Wu, V.H.; Allevato, M.M.; Gilardi, M.; He, Y.; Luis Callejas-Valera, J.; Vitale-Cross, L.; Martin, D.; Amornphimoltham, P.; McDermott, J.; et al. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. *Nat. Commun.* **2019**, *10*, 5546. [[CrossRef](#)] [[PubMed](#)]
83. Mann, J.E.; Kulkarni, A.; Birkeland, A.C.; Kafelghazal, J.; Eisenberg, J.; Jewell, B.M.; Ludwig, M.L.; Spector, M.E.; Jiang, H.; Carey, T.E.; et al. The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel. *Head Neck* **2019**, *41*, 3114–3124. [[CrossRef](#)] [[PubMed](#)]
84. Katoh, M. Function and cancer genomics of FAT family genes (review). *Int. J. Oncol.* **2012**, *41*, 1913–1918. [[CrossRef](#)] [[PubMed](#)]
85. Kim, K.T.; Kim, B.-S.; Kim, J.H. Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma. *Head Neck* **2016**, *38* (Suppl. 1), E2021–E2029. [[CrossRef](#)] [[PubMed](#)]
86. Kriegs, M.; Clauditz, T.S.; Hoffer, K.; Bartels, J.; Buhs, S.; Gerull, H.; Zech, H.B.; Bußmann, L.; Struve, N.; Rieckmann, T.; et al. Analyzing expression and phosphorylation of the EGF receptor in HNSCC. *Sci. Rep.* **2019**, *9*, 13564. [[CrossRef](#)]

87. Temam, S.; Kawaguchi, H.; El-Naggar, A.K.; Jelinek, J.; Tang, H.; Liu, D.D.; Lang, W.; Issa, J.-P.; Lee, J.J.; Mao, L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **2007**, *25*, 2164–2170. [[CrossRef](#)] [[PubMed](#)]
88. Fan, R.; Kim, N.-G.; Gumbiner, B.M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 2569–2574. [[CrossRef](#)]
89. Omori, H.; Nishio, M.; Masuda, M.; Miyachi, Y.; Ueda, F.; Nakano, T.; Sato, K.; Mimori, K.; Taguchi, K.; Hikasa, H.; et al. YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma. *Sci. Adv.* **2020**, *6*, eaay3324. [[CrossRef](#)]
90. Bichsel, S.J.; Tamaskovic, R.; Stegert, M.R.; Hemmings, B.A. Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase by the hMOB1 protein. *J. Biol. Chem.* **2004**, *279*, 35228–35235. [[CrossRef](#)]
91. Zhang, L.; Tang, F.; Terracciano, L.; Hynx, D.; Kohler, R.; Bichet, S.; Hess, D.; Cron, P.; Hemmings, B.A.; Hergovich, A.; et al. NDR functions as a physiological YAP1 kinase in the intestinal epithelium. *Curr. Biol. CB* **2015**, *25*, 296–305. [[CrossRef](#)]
92. Enomoto, A.; Kido, N.; Ito, M.; Morita, A.; Matsumoto, Y.; Takamatsu, N.; Hosoi, Y.; Miyagawa, K. Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38 (STK38). *Oncogene* **2008**, *27*, 1930–1938. [[CrossRef](#)] [[PubMed](#)]
93. Hergovich, A. The Roles of NDR Protein Kinases in Hippo Signalling. *Genes* **2016**, *7*, 21. [[CrossRef](#)] [[PubMed](#)]
94. Cheng, H.; Yang, X.; Si, H.; Saleh, A.D.; Xiao, W.; Coupar, J.; Gollin, S.M.; Ferris, R.L.; Issaeva, N.; Yarbrough, W.G.; et al. Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. *Cell Rep.* **2018**, *25*, 1332–1345.e5. [[CrossRef](#)] [[PubMed](#)]
95. Li, J.; Li, Z.; Wu, Y.; Wang, Y.; Wang, D.; Zhang, W.; Yuan, H.; Ye, J.; Song, X.; Yang, J.; et al. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma. *Cell Death Dis.* **2019**, *10*, 603. [[CrossRef](#)] [[PubMed](#)]
96. Li, Z.; Wang, Y.; Zhu, Y.; Yuan, C.; Wang, D.; Zhang, W.; Qi, B.; Qiu, J.; Song, X.; Ye, J.; et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. *Mol. Oncol.* **2015**, *9*, 1091–1105. [[CrossRef](#)]
97. Truong, A.B.; Kretz, M.; Ridky, T.W.; Kimmel, R.; Khavari, P.A. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. *Genes Dev.* **2006**, *20*, 3185–3197. [[CrossRef](#)]
98. Euskirchen, G.; Auerbach, R.K.; Snyder, M. SWI/SNF chromatin-remodeling factors: Multiscale analyses and diverse functions. *J. Biol. Chem.* **2012**, *287*, 30897–30905. [[CrossRef](#)]
99. Saladi, S.V.; Ross, K.; Karaayvaz, M.; Tata, P.R.; Mou, H.; Rajagopal, J.; Ramaswamy, S.; Ellisen, L.W. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. *Cancer Cell* **2017**, *31*, 35–49. [[CrossRef](#)]
100. Moleirinho, S.; Chang, N.; Sims, A.H.; Tilston-Lünel, A.M.; Angus, L.; Steele, A.; Boswell, V.; Barnett, S.C.; Ormandy, C.; Faratian, D.; et al. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. *Oncogene* **2013**, *32*, 1821–1830. [[CrossRef](#)]
101. Yu, J.; Zheng, Y.; Dong, J.; Klusza, S.; Deng, W.-M.; Pan, D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. *Dev. Cell* **2010**, *18*, 288–299. [[CrossRef](#)]
102. Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP/TAZ at the Roots of Cancer. *Cancer Cell* **2016**, *29*, 783–803. [[CrossRef](#)] [[PubMed](#)]
103. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. *Science* **2015**, *347*, 1260419. [[CrossRef](#)] [[PubMed](#)]
104. Wang, Y.; Gersten, A.; Moleirinho, S.; Gunn-Moore, F.J.; Reynolds, P.A.; Prystowsky, M.B. Fibroblasts in Head and Neck Squamous Cell Carcinoma Associated With Perineural Invasion Have High-Level Nuclear Yes-Associated Protein (YAP) Expression. *Acad. Pathol.* **2015**, *2*, 2374289515616972. [[CrossRef](#)] [[PubMed](#)]
105. Ge, L.; Smail, M.; Meng, W.; Shyr, Y.; Ye, F.; Fan, K.-H.; Li, X.; Zhou, H.-M.; Bhowmick, N.A. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. *PLoS ONE* **2011**, *6*, e27529. [[CrossRef](#)]
106. Wei, Z.; Wang, Y.; Li, Z.; Yuan, C.; Zhang, W.; Wang, D.; Ye, J.; Jiang, H.; Wu, Y.; Cheng, J. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: Correlation with clinicopathological features and patients' prognosis. *J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol.* **2013**, *42*, 747–754. [[CrossRef](#)]
107. Eun, Y.-G.; Lee, D.; Lee, Y.C.; Sohn, B.H.; Kim, E.H.; Yim, S.Y.; Kwon, K.H.; Lee, J.-S. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. *Oncotarget* **2017**, *8*, 111130–111143. [[CrossRef](#)]
108. García-Escudero, R.; Segrelles, C.; Dueñas, M.; Pombo, M.; Ballestín, C.; Alonso-Riaño, M.; Nenclares, P.; Álvarez-Rodríguez, R.; Sánchez-Aniceto, G.; Ruíz-Alonso, A.; et al. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. *Oral Oncol.* **2018**, *79*, 55–63. [[CrossRef](#)]
109. Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Anzai, Y.; Brizel, D.M.; Bruce, J.Y.; Busse, P.M.; Caudell, J.J.; Cmelak, A.J.; et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J. Natl. Compr. Cancer Netw.* **2020**, *18*, 873–898. [[CrossRef](#)]
110. Yoshikawa, K.; Noguchi, K.; Nakano, Y.; Yamamura, M.; Takaoka, K.; Hashimoto-Tamaoki, T.; Kishimoto, H. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. *Int. J. Oncol.* **2015**, *46*, 2364–2370. [[CrossRef](#)]
111. Shriwas, O.; Arya, R.; Mohanty, S.; Mohapatra, P.; Kumar, S.; Rath, R.; Kaushik, S.R.; Pahwa, F.; Murmu, K.C.; Majumdar, S.K.D.; et al. RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway. *Br. J. Cancer* **2021**, *124*, 2004–2016. [[CrossRef](#)]

112. Ehsanian, R.; Brown, M.; Lu, H.; Yang, X.P.; Pattatheyl, A.; Yan, B.; Duggal, P.; Chuang, R.; Doondeea, J.; Feller, S.; et al. YAP dysregulation by phosphorylation or Δ Np63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. *Oncogene* **2010**, *29*, 6160–6171. [[CrossRef](#)] [[PubMed](#)]
113. Albanell, J.; Codony-Servat, J.; Rojo, F.; Del Campo, J.M.; Sauleda, S.; Anido, J.; Raspall, G.; Giralt, J.; Roselló, J.; Nicholson, R.I.; et al. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. *Cancer Res.* **2001**, *61*, 6500–6510. [[PubMed](#)]
114. Seland, T.M.; Husvik, C.; Koppang, H.S.; Boysen, M.; Sandvik, L.; Clausen, O.P.F.; Christoffersen, T.; Bryne, M. A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas. *J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol.* **2008**, *37*, 535–542. [[CrossRef](#)] [[PubMed](#)]
115. Judd, N.P.; Winkler, A.E.; Murillo-Sauca, O.; Brotman, J.J.; Law, J.H.; Lewis, J.S.; Dunn, G.P.; Bui, J.D.; Sunwoo, J.B.; Uppaluri, R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. *Cancer Res.* **2012**, *72*, 365–374. [[CrossRef](#)] [[PubMed](#)]
116. Uppaluri, R.; Winkler, A.E.; Lin, T.; Law, J.H.; Haughey, B.H.; Nussenbaum, B.; Paniello, R.C.; Rich, J.T.; Diaz, J.A.; Michel, L.P.; et al. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2017**, *23*, 2186–2194. [[CrossRef](#)] [[PubMed](#)]
117. Zhao, Y.; Adjei, A.A. The clinical development of MEK inhibitors. *Nat. Rev. Clin. Oncol.* **2014**, *11*, 385–400. [[CrossRef](#)] [[PubMed](#)]
118. Mudianto, T.; Campbell, K.M.; Webb, J.; Zolkind, P.; Skidmore, Z.L.; Riley, R.; Barnell, E.K.; Ozgenc, I.; Giri, T.; Dunn, G.P.; et al. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **2021**, *27*, 2326–2339. [[CrossRef](#)]
119. Bushweller, J.H. Targeting Transcription Factors in Cancer - from Undruggable to Reality. *Nat Rev Cancer* **2019**, *19*, 611–624. [[CrossRef](#)]
120. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.-J.; Anders, R.A.; Liu, J.O.; Pan, D. Genetic and Pharmacological Disruption of the TEAD-YAP Complex Suppresses the Oncogenic Activity of YAP. *Genes Dev* **2012**, *26*, 1300–1305. [[CrossRef](#)]
121. Schmidt-Erfurth, U.; Hasan, T. Mechanisms of Action of Photodynamic Therapy with Verteporfin for the Treatment of Age-Related Macular Degeneration. *Surv Ophthalmol* **2000**, *45*, 195–214. [[CrossRef](#)]
122. Gibault, F.; Corvaisier, M.; Bailly, F.; Huet, G.; Melnyk, P.; Cotellet, P. Non-Photoinduced Biological Properties of Verteporfin. *Curr Med Chem* **2016**, *23*, 1171–1184. [[CrossRef](#)] [[PubMed](#)]
123. Tang, T.T.; Konradi, A.W.; Feng, Y.; Peng, X.; Ma, M.; Li, J.; Yu, F.-X.; Guan, K.-L.; Post, L. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. *Mol. Cancer Ther.* **2021**, *20*, 986–998. [[CrossRef](#)] [[PubMed](#)]
124. Wang, W.; Li, N.; Li, X.; Tran, M.K.; Han, X.; Chen, J. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. *Cell Rep.* **2015**, *13*, 524–532. [[CrossRef](#)] [[PubMed](#)]
125. Araujo, J.; Logothetis, C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. *Cancer Treat. Rev.* **2010**, *36*, 492–500. [[CrossRef](#)]
126. Dunn, L.A.; Riaz, N.; Fury, M.G.; McBride, S.M.; Michel, L.; Lee, N.Y.; Sherman, E.J.; Baxi, S.S.; Haque, S.S.; Katabi, N.; et al. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* **2020**, *106*, 564–570. [[CrossRef](#)]
127. Zhang, B.; Zhang, Y.; Zhang, J.; Liu, P.; Jiao, B.; Wang, Z.; Ren, R. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. *Adv. Sci. Weinh. Baden-Wurtt. Ger.* **2021**, *8*, e2100250. [[CrossRef](#)]
128. Pifer, P.; Kumar, M.; Yang, L.; Xie, T.; Frederick, M.; Hefner, A.; Beadle, B.M.; Dhawan, A.; Molkenkine, D.; Molkenkine, J.; et al. Focal Adhesion Kinase Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma in a p53-Dependent Manner. *Int. J. Radiat. Oncol.* **2022**, *112*, e12. [[CrossRef](#)]
129. Chan, P.; Han, X.; Zheng, B.; DeRan, M.; Yu, J.; Jarugumilli, G.K.; Deng, H.; Pan, D.; Luo, X.; Wu, X. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. *Nat. Chem. Biol.* **2016**, *12*, 282–289. [[CrossRef](#)]
130. Santos, R.; Ursu, O.; Gaulton, A.; Bento, A.P.; Donadi, R.S.; Bologa, C.G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T.I.; et al. A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discov.* **2017**, *16*, 19–34. [[CrossRef](#)]
131. Campbell, A.P.; Smrcka, A.V. Targeting G protein-coupled receptor signalling by blocking G proteins. *Nat. Rev. Drug Discov.* **2018**, *17*, 789–803. [[CrossRef](#)]
132. Wu, V.; Yeerna, H.; Nohata, N.; Chiou, J.; Harismendy, O.; Raimondi, F.; Inoue, A.; Russell, R.B.; Tamayo, P.; Gutkind, J.S. Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. *J. Biol. Chem.* **2019**, *294*, 11062–11086. [[CrossRef](#)] [[PubMed](#)]
133. Coles, G.L.; Cristea, S.; Webber, J.T.; Levin, R.S.; Moss, S.M.; He, A.; Sangodkar, J.; Hwang, Y.C.; Arand, J.; Drainas, A.P.; et al. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. *Cancer Cell* **2020**, *38*, 129–143.e7. [[CrossRef](#)] [[PubMed](#)]
134. Kauko, O.; O'Connor, C.M.; Kuleskiy, E.; Sangodkar, J.; Aakula, A.; Izadmehr, S.; Yetukuri, L.; Yadav, B.; Padzik, A.; Laajala, T.D.; et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. *Sci. Transl. Med.* **2018**, *10*, eaaq1093. [[CrossRef](#)] [[PubMed](#)]

135. Ho, W.S.; Wang, H.; Maggio, D.; Kovach, J.S.; Zhang, Q.; Song, Q.; Marincola, F.M.; Heiss, J.D.; Gilbert, M.R.; Lu, R.; et al. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. *Nat. Commun.* **2018**, *9*, 2126. [[CrossRef](#)] [[PubMed](#)]
136. Jung, Y.-S.; Park, J.-I. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond β -catenin and the destruction complex. *Exp. Mol. Med.* **2020**, *52*, 183–191. [[CrossRef](#)] [[PubMed](#)]
137. Morrone, S.; Cheng, Z.; Moon, R.T.; Cong, F.; Xu, W. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 1500–1505. [[CrossRef](#)]
138. Huang, S.-M.A.; Mishina, Y.M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G.A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* **2009**, *461*, 614–620. [[CrossRef](#)]
139. Azzolin, L.; Zanconato, F.; Bresolin, S.; Forcato, M.; Basso, G.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Role of TAZ as mediator of Wnt signaling. *Cell* **2012**, *151*, 1443–1456. [[CrossRef](#)]
140. Juan, W.C.; Hong, W. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. *Genes* **2016**, *7*, 55. [[CrossRef](#)]